• Product NameBMS-986020
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityBMS-986020 is an LPA1 antagonist. target: LPA1 BMS-986020 is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis. BMS-986020 selectively inhibits the LPA receptor, which is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a host of diverse biological functions, such as cell proliferation, platelet aggregation, smooth muscle contraction and others.
• Target NameLPA Receptor inhibitor
• CAS No. 1257213-50-5
• Calculated MW 482.53
• Formulation C29H26N2O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
  Pathways:GPCR/G Protein
  Receptor:LPA1
  Boling pt:
  Melting pt:
  Solubility:DMSO: 64 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Kihara Y et al. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015 May 1;333(2):171-7.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting